Thermo Fisher Scientific Inc. Strategy Analysis

Continue to invest in and accelerate the development of advanced mass spectrometry technologies, such as the Stellar and Orbitrap Astral mass spectrometers, to advance clinical research and proteomics.

Further expand electron microscopy capabilities by integrating advanced analytical technologies into user-friendly workflows, enabling the development of advanced materials.

Introduce new additions to the Gibco™ CTS™ Detachable Dynabeads™ platform to further enhance development and manufacturing of life-changing cell therapies.

Develop and launch advanced DNA/RNA isolation kits, such as the Applied Biosystems™ MagMAX™ Sequential DNA/RNA Kit, to help researchers identify unique insights into cancer-causing genetic alterations.

Continue to expand pharma services and clinical research capabilities in the U.S. and Europe to meet customers' current and future needs.

Actively promote the Accelerator™ Drug Development solution, leveraging combined contract development and manufacturing and clinical research capabilities to improve pharma and biotech customers' return on R&D investments.

Advance proteomics research by integrating Olink™ technology and participating in large-scale proteomics studies, such as the UK Biobank Pharma Proteomics Project.

Establish centers of excellence for proteomics, such as the Thermo Fisher Scientific Center of Excellence for Proteomics at UAMS, to provide researchers and doctors with access to industry-leading technologies.

Partner with organizations like the National Cancer Institute to support precision medicine trials, using next-generation sequencing technology to match patients with appropriate clinical trial cancer treatments.

Enhance commercial capabilities, including expansion of geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects and other expenditures to enhance the customer experience.

Improve cost efficiencies from its Practical Process Improvement (PPI) business system to address inflation, including reduced costs resulting from implementing continuous improvement methodologies, global sourcing initiatives, a lower cost structure following restructuring actions including headcount reductions and consolidation of facilities, and low cost region manufacturing.

Improve customer allegiance by engaging and empowering all colleagues to find a better way every day, helping us to drive share gain and improve quality, productivity and customer allegiance.

Advance precision medicine through next-generation sequencing technology to test patients' blood and bone marrow and help match them more quickly with appropriate clinical trial cancer treatments.

Pinpoint the key causes of diseases and identify drug targets through proteomics research, such as the UK Biobank Pharma Proteomics Project.

Improve transplant diagnostics by introducing new testing services to help doctors monitor a patient's risk of rejection following a kidney transplant and evaluate a patient's risk for early rejection based on their unique immune profile.

Streamline environmental testing in industrial and applied settings with the Thermo Scientific™ Dionex™ Inuvion™ ion chromatography system.

Streamline trace elemental analysis for environmental, food, industrial and research laboratories with the Thermo Scientific™ iCAP™ MX Series ICP-MS.

Advance materials science discovery and development by enabling scientists to view structures at the nanometer scale with scanning electron microscopes (SEMs).

Reveal secrets about life on earth by using powerful and portable SEMs to examine microscopic samples of minerals and microorganisms in extreme environments.

Continue to innovate in the field of transplant diagnostics, from pre-transplant tests to ensure the best possible organ match to post-transplant monitoring.

Help doctors monitor a patient's risk of rejection following a kidney transplant with a new non-invasive urine test that analyzes genetic biomarkers.

Help doctors evaluate a patient's risk for early rejection based on their unique immune profile with a new pre-transplant risk assessment test.

Reduce inventory levels through the Practical Process Improvement (PPI) Business System.

Improve supply-chain performance through the Practical Process Improvement (PPI) Business System.

Increase capacity through the Practical Process Improvement (PPI) Business System.

Run operations more effectively through the Practical Process Improvement (PPI) Business System.

Leverage generative artificial intelligence capabilities and deploy other digital tools to increase productivity, make jobs easier and help better serve customers.